What Fate Therapeutics does

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived CAR T-cell and CAR-NK cell therapies for autoimmune diseases and cancer. The company's proprietary induced pluripotent stem cell (iPSC) platform enables standardized, multiplexed-engineered cell products that are pre-manufactured, cryopreserved, and available on-demand — eliminating the need for patient-specific autologous manufacturing and reducing conditioning chemotherapy requirements through its Alloimmune Defense Technology. The pipeline centers on FT819 (anti-CD19 CAR T for lupus nephritis and other B-cell-mediated autoimmune diseases), FT836 (MICA/B-targeted CAR T for solid tumors including colorectal cancer), FT839 (dual-CAR T for autoimmune indications, IND planned H2 2026), FT522 (CAR-NK with Alloimmune Defense Technology), and FT825. The lead candidate FT819 received FDA RMAT designation and was selected for the FDA CDRP pilot program in May 2026, and a registrational Phase 2 RECLAIM-LN trial (~53 patients) is planned for H2 2026.

The company operates 16 clinical trial sites across the U.S., U.K., and EU and is currently pre-revenue from a commercial product standpoint — Q1 2026 revenue of $1.3M reflects collaboration-related and other non-product sources only. Fate Therapeutics is publicly traded on NASDAQ under ticker FATE, headquartered in San Diego, CA, with a market capitalization of approximately $250.7M as of June 2026. The business model remains R&D-intensive with cash funded primarily through equity financings — the most recent being a $100M combined underwritten offering and private placement in March 2024 — and the company held $174.8M in liquid resources as of Q1 2026, providing an estimated 5.7 quarters of runway. The company is positioning for a transition from clinical-stage to commercial-stage operations, evidenced by the June 2026 appointment of Laura Hamill (former Gilead EVP overseeing ~$22B in annual revenue) to the Board of Directors.

Name

Fate Therapeutics

Legal name

Fate Therapeutics, Inc.

Website

https://fatetherapeutics.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf CAR T-cell and CAR-NK therapies from its proprietary iPSC platform for autoimmune diseases and cancer. Lead asset FT819 targets lupus nephritis with a Phase 2 registrational trial planned for H2 2026.

Ownership category

akta.pro rank

Product category

Cell Therapy / Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Cell therapy platform
• Immuno-oncology pipeline
• CAR T-cell therapies
• IPSC-derived therapies
• Autoimmune disease treatments

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Product Revenue: Pre-revenue clinical-stage company. No products approved for commercial sale. Revenue will come from approved cell therapy products following successful clinical trials and regulatory approvals. Current Q1 2026 revenue of $1.3 million appears to be from collaborations or other sources.
2. Financing/Investment: $100 million financing completed March 2024 combining underwritten stock offering and private placement to fund clinical trials, manufacturing, and research activities

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived CAR T-cell and CAR NK cell therapy candidates for autoimmune diseases and cancer. The company's core platform enables scalable, pre-manufactured, frozen cell products that can be administered on demand without patient-specific manufacturing, with lead candidates targeting B-cell mediated autoimmune disorders (SLE, lupus nephritis) and hematologic and solid tumor malignancies.

Product overview

Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf CAR T and CAR NK cell therapies derived from induced pluripotent stem cells (iPSCs) for the treatment of autoimmune diseases and cancer. The company's product portfolio centers on its iPSC platform, which enables scalable manufacturing of multiplexed-engineered cell products. Key pipeline candidates include FT819 (anti-CD19 CAR T for lupus/SLE, Phase 1), FT836 (MICA/B-targeted CAR T for solid tumors, Phase 1), FT839 (dual-CAR T for autoimmune diseases, preclinical), FT522 (CAR NK for autoimmunity, preclinical), and FT825 (immuno-oncology candidate). The company is advancing toward a potential transition to a commercial-stage biopharma with its lead asset FT819 receiving FDA RMAT designation and selection into the CDRP program for lupus nephritis.

Differentiator

Problem solved

Functional benefit

Products and services

• FT819 Off-the-shelf anti-CD19 CAR T-cell therapy derived from iPSCs, designed for outpatient administration and on-demand availability for patients with B-cell related autoimmune disorders including systemic lupus erythematosus (SLE) and lupus nephritis. Currently in Phase 1 clinical testing with planned Phase 2 RECLAIM-LN registrational trial.
• FT825 iPSC-derived cell therapy candidate included in the company's immuno-oncology pipeline for cancer treatment.
• FT836 MICA/B-targeted CAR T-cell therapy designed to overcome solid tumor escape mechanisms and avoid the requirement for conditioning chemotherapy. In Phase 1 clinical testing in metastatic colorectal cancer with reported 19% and 52% tumor reductions in evaluable patients and greater than 50% reduction in CEA levels.
• FT839 Next-generation dual-CAR T-cell candidate targeting multiple antigens for treatment of autoimmune diseases. Preclinical data shows potent activity in rheumatoid arthritis patient samples without conditioning chemotherapy. IND filing planned for H2 2026.
• FT522 CAR NK cell therapy with Alloimmune Defense Technology designed to target multiple pathogenic cell types and circumvent lympho-conditioning in systemic autoimmunity. Demonstrates functional persistence of allogeneic cell therapies without conditioning chemotherapy.

Quantifiable outcome

• 21 SLE patients achieved rapid and sustained clinical improvements with favorable tolerability profile including no dose-limiting toxicity, Grade ≥3 cytokine release syndrome, or neurotoxicity
• +5 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Laura Hamill (Individual - Board Director)minorOthers · 15 June 2026Laura Hamill appointed to Board of Directors effective June 15, 2026. Former Executive Vice President of Worldwide Commercial Operations at Gilead Sciences where she oversaw approximately $22 billion in annual revenue. Her commercial and strategic management expertise is intended to help position Fate Therapeutics for its expected transition to a commercial-stage company.
• Kamal Adawi (Individual - CFO)minorOthers · 20 October 2025Kamal Adawi appointed as Chief Financial Officer effective October 20, 2025. Adawi has over 20 years of experience in life sciences financial leadership, including roles at Exagen Inc. and Mindera Health.
• Clinical Trial Sites (16 sites)coreStrategic or Co-development Partner16 clinical sites across U.S., U.K., and EU conducting Phase 1 trials for FT819 in autoimmune diseases (15 SLE patients and 4 systemic sclerosis patients treated to date). Regulatory approvals obtained from FDA, UK MHRA, and EU EMA.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Allogene Therapeutics: Allogene is the closest direct peer — an allogeneic (off-the-shelf) CAR-T developer with a pipeline targeting B-cell malignancies and autoimmune diseases. Both companies compete to demonstrate off-the-shelf CAR-T can replace autologous approaches.
• Kyverna Therapeutics: Kyverna Therapeutics develops autologous and allogeneic CAR-T cell therapies for autoimmune diseases. Competes with Fate in the autoimmune CAR-T market with overlapping indications including SLE and lupus nephritis.
• Cellectis: Cellectis is a clinical-stage biotech developing allogeneic CAR-T cell therapies using TALEN gene editing. Competes with Fate in the off-the-shelf CAR-T space with a similar platform-based approach to multiplexed cell engineering.
• Atara Biotherapeutics: Atara develops allogeneic T-cell and CAR-T immunotherapies (EBV-specific and off-the-shelf CAR-T) for hematologic malignancies and solid tumors. Competes with Fate in the off-the-shelf cell therapy space with overlapping oncology and autoimmune targets.
• Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing for hematologic malignancies and autoimmune diseases. Directly competes with Fate on off-the-shelf, gene-edited cell therapy platform technology.
• Crispr Therapeutics: Crispr Therapeutics develops gene-edited allogeneic CAR-T cell therapies (Casgevy) with Vertex as a partner. Competes directly with Fate's iPSC-derived off-the-shelf platform and is also expanding into autoimmune indications.
• Precision Biosciences: Precision Biosciences develops allogeneic CAR-T cell therapies using ARCUS gene editing. Competes with Fate in off-the-shelf cell therapy development for oncology and autoimmune indications.
• Cabaletta Bio: Cabaletta Bio is a clinical-stage biotech developing CAR-T cell therapies specifically for autoimmune diseases including SLE and lupus nephritis. Direct competitor to Fate's FT819 in the autoimmune CAR-T space.

Broad incumbents

• Bristol-Myers Squibb: BMS markets Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T), making it a leading CAR-T incumbent. BMS's commercial reach, manufacturing scale, and ongoing pipeline expansion represent a significant competitive threat to Fate's off-the-shelf approach.
• Gilead Sciences (Kite): Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus, the leading commercial autologous CAR-T therapies. As a broad incumbent with established manufacturing, sales force, and physician relationships, Gilead is the primary commercial competitor Fate will face at launch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/fatethx
• Facebookfacebook.com/148869618488930
• LinkedInlinkedin.com/company/fate-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds19 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fate Therapeutics